Plain-English translation of NCT07728383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a new way to deliver semaglutide, a medication that helps people feel fuller and lose weight. Researchers are comparing three approaches: a new liquid form you apply under your tongue, the standard semaglutide tablet (Wegovy), and a placebo (inactive liquid). The goal is to see if the liquid form works as well as or better than the tablet, and to understand how your body processes it.
Semaglutide has shown promise for weight loss, but researchers want to explore whether delivering it as a liquid under the tongue might work better, be easier to use, or cause fewer side effects than the current tablet form.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new liquid medication, the standard tablet, or a placebo, all taken daily. If you receive the tablet, you'll start with a lower dose and gradually increase it over 90 days. The study involves clinic visits where researchers will check your weight, take blood samples to measure how your body processes the medication, and monitor you for any side effects or health concerns.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Gila Therapeutics, Inc.
Enrollment target
~40 participants
Started
June 2026
Primary completion
May 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.